ArticleObstetrics & gynecology science2024
Cervical cancer in Thailand: 2023 update.
Article in Obstetrics & gynecology science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 9 citations in OpenAlex.
- Three-year post-recurrence survival outcome by leukopenia grade 2+ during systemic chemotherapy in recurrent cervical cancer.Obstetrics & gynecology science · 2026Article
- Cytotoxic Effect ofCancer management and research · 2026Article
- Tracking cancer hospitalizations: seventeen-year sex-specific trends in nationally representative hospitalization data on malignant neoplasms in Thailand (2007-2023).BMC public health · 2025Article
- Risk of CIN2+ in women aged >60 years with abnormal cervical cancer screening: a multicenter retrospective cohort study from the Thai Gynecologic Cancer Society research group.Journal of gynecologic oncology · 2025Article
- Identification of volatile organic compound as a novel modality for cervical cancer detection.Obstetrics & gynecology science · 2025Article
- Evaluation of cervical cancer screening strategies in women living with HIV in Thailand.Cancer communications (London, England) · 2025Article
- Factors Predicting Sexual Satisfaction of Thai Women with Cervical Cancer After Complete Treatment at Least One Year and Their Spouses.Healthcare (Basel, Switzerland) · 2025Article
- Unlocking economic gains: the impact of image-guided brachytherapy on cervical cancer treatment in Thailand.Frontiers in public health · 2025Article
- Sexual Dysfunction in Patient's Diagnosed with Cervical Cancer in Comparison to the Healthy Female Population.Asian Pacific journal of cancer prevention : APJCP · 2024Observational
- Anti-Cancer Potential of Isoflavone-Enriched Fraction from Traditional Thai Fermented Soybean against Hela Cervical Cancer Cells.International journal of molecular sciences · 2024Article
- Perceived Feasibility and Acceptability of a Self-Collected HPV DNA Testing Policy for Cervical Cancer Screening in Thailand.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer continues to pose a challenge to the health of Thai women, as the second most common cancer after breast cancer. Since high-risk human papillomavirus (HPV) types are the main cause for cervical cancer, cervical cancer screening and HPV vaccination are necessary to reduce the incidence of this disease. At present, the World Health Organization hopes to reduce the incidence of cervical cancer to 4 or less cases per 100,000 women-years using 90%- 70%-90% intervention by 2030. The first intervention involves vaccinating 90% of women aged 15 years with the HPV vaccine. The second intervention involves screening 70% of women between the ages of 35 and 45 years using a high-performance screening test. The third intervention involves detecting cervical lesions in 90% of affected women to enable diagnosis and treatment. In this context, this study reviews trends in the incidence and mortality rates of cervical cancer in Thailand, in addition to providing an up-to-date overview of the causes and necessary risk factors for cervical cancer, as well as reporting on cervical screening and HPV vaccination rates and cervical cancer during the coronavirus disease 2019 (COVID-19) pandemic. This study may prove useful for the formulation of policy aimed at eliminating cervical cancer in Thailand, such as the implementation of a free HPV vaccine service and providing athome kits for cervical screening through clinics and pharmacies. In addition, this review also highlights the need for further research on the effects of the COVID-19 pandemic on cervical cancer screening rates in Thailand.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.